Compsorbin - Amyndas Pharmaceuticals
Alternative Names: AMY-301Latest Information Update: 03 Nov 2022
At a glance
- Originator Amyndas Pharmaceuticals
- Class Anti-inflammatories; Peptides
- Mechanism of Action Complement factor H inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 22 Sep 2022 Preclinical trials in Autoimmune disorders in USA (unspecified route), before September 2022 (Amyndas Pharmaceuticals pipeline, September 2022)